Potential Clinical Utility of Serum HER-2/neu Oncoprotein Concentrations in Patients with Breast Cancer | Zendy

Walter P. Carney | Zendy; Rainer Neumann | Zendy; Allan Lipton | Zendy; Kim Leitzel | Zendy; Suhail M. Ali | Zendy; Christopher P. Price | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Potential Clinical Utility of Serum HER-2/neu Oncoprotein Concentrations in Patients with Breast Cancer

Author(s) -

Walter P. Carney,

Rainer Neumann,

Allan Lipton,

Kim Leitzel,

Suhail M. Ali,

Christopher P. Price

Publication year - 2003

Publication title -

clinical chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.705

H-Index - 218

eISSN - 1530-8561

pISSN - 0009-9147

DOI - 10.1373/49.10.1579

Subject(s) - medicine , breast cancer , oncology , metastatic breast cancer , chemotherapy , disease , cancer , her2/neu , mammary gland , hormone therapy , ca15 3

The HER-2/neu oncogene and its p185 receptor protein are indicators of a more aggressive form of breast cancer. HER-2/neu status guides Herceptin therapy, specifically directed to the extracellular domain (ECD) of the HER-2/neu oncoprotein. The HER-2/neu ECD is shed from cancer cells into the circulation and is measurable by immunoassay.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research